IDEAYA Biosciences is Drug Discovery in United States that focus on IDEAYA Biosciences Inc business. Founded in 2015. They cover business area such as IDEAYA Biosciences Inc, development, target therapeutic, patient population, molecular diagnostic, capability, multiple class, precision medicine, direct targeting, oncogenic pathway, synthetic lethality, PKC, an inhibitor, genetically-define cancer, GNAQ.
2015
( 9 years old in 2024 )
IDEAYA Biosciences Inc
-
7000 Shoreline Court
Suite 350
South San Francisco, CA 94080
United States
Private
IDEAYA Biosciences Incdevelopmenttarget therapeuticpatient populationmolecular diagnosticcapabilitymultiple classprecision medicinedirect targetingoncogenic pathwaysynthetic lethalityPKCan inhibitorgenetically-define cancerGNAQ
* We use standard office opening hours in near IDEAYA Biosciences's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
IDEAYA Biosciences is Drug Discovery business from United States that founded in 2015 (9 years old in 2024), IDEAYA Biosciences business is focusing on IDEAYA Biosciences Inc.
IDEAYA Biosciences headquarter office and corporate office address is located in 7000 Shoreline Court Suite 350 South San Francisco, CA 94080 United States.
IDEAYA Biosciences was founded in United States.
In 2024, IDEAYA Biosciences is currently focus on IDEAYA Biosciences Inc sector.
Above is snippet of Google Trends for "IDEAYA Biosciences Inc" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with IDEAYA Biosciences, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
